Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind, Placebo-Controlled, 12-Week Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Moderate to Severe Spasticity Resulting From Chronic, Incomplete Spinal Cord Injury

NCT00041717 is registered in ClinicalTrials.gov with Acorda Therapeutics as lead sponsor.

NCT NCT00041717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00041717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind, Placebo-Controlled, 12-Week Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Moderate to Severe Spasticity Resulting From Chronic, Incomplete Spinal Cord Injury
Lead sponsor
Acorda Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2002
Completion date
May 31, 2004
Enrollment
213 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

muscle spasticity, spinal cord injury